{
    "medicine_id": "cf12ebcec268d3d58f6eb26814c5b6b454679f7e",
    "platform_id": "DB13905",
    "metadata": {
        "name": "Anascorp 3 8 mg 1mL Injection powder lyophilized for solution",
        "composition": "3 8 mg 1mL Scorpion centruroides immune Fab2 antivenin equine",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated for treatment of clinical signs of scorpion envenomation L2195 L2196",
            "contraindications": {
                "disease": "The most common adverse reactions observed in 2 of patients in the clinical studies for Anascorp were vomiting pyrexia rash nausea and pruritus FDA label Severe hypersensitivity reactions including anaphylaxis may occur with Anascorp L2203 FDA label Diligent patient monitoring for hypersensitivity reactions and preparation for intravenous therapy using epinephrine corticosteroids and diphenhydramine hydrochloride is recommended during the infusion If an anaphylactic reaction occurs during the Anascorp infusion case administration immediately and administer warranted emergency medical care FDA label Patients with existing allergies to horse protein are at a higher risk for developing anaphylactic reactions Patients who have had previous therapy with Anascorp or another equine antivenom antitoxin may have become sensitized to equine proteins and be at an elevated risk for a severe hypersensitivity reaction FDA label Trace amounts of cresol from the manufacturing process are contained in Anascorp Localized reactions and generalized myalgias have been observed with the use of cresol as an injectable excipient FDA label Monitor patients with follow up visit s for signs and symptoms of delayed allergic reactions or serum sickness symptoms include rash fever myalgia arthralgia and treat appropriately if necessary Eight out of 1 534 0 5 patients in the clinical trials exhibited symptoms suggestive of serum sickness FDA label Anascorp is created from equine horse plasma it may carry a risk of transmitting infectious agents e g viruses FDA label The following adverse reactions have been identified during post approval use of Anascorp chest tightness palpitations rash and pruritus Because these reactions are reported voluntarily from a population of uncertain size it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure FDA label",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "In 2008 15 522 scorpion envenomations were reported to the National Poison Data System in the USA with one fatality ocurring in a toddler In the United States Centruroides _sculpturatus_ commonly known as the Arizona bark scorpion is the only scorpion species whose venom is toxic to humans Though most _Centruroides_ scorpion stings in adults are well tolerated with minimal effects pediatric patients are quite susceptible to signicant morbidity from the venom L2207 In a pharmacokinetic study of 1534 patients 95 100 of the study group were relieved of systemic signs associated with scorpion envenomation in less than four hours after initiating Anascorp treatment In the historical control database only 3 1 of patients experienced relief of symptoms within 4 hours of hospital admission FDA label Clinical manifestations of scorpion sting and envenomation include sweating salivation cool extremities priapism hypertension or hypotension and tachycardia L2201 In 1396 1534 patients the average time from the start of Anascorp infusion to the resolution of clinical signs and symptoms of envenomation was 1 42 hours 0 2 to 20 5 hours Pediatric patients were found to experience a slightly faster time to resolution 1 28 0 8 hours compared to that of adult patients 1 91 1 4 hours The time to resolution of symptoms was not affected by use of sedatives 474 patients who received sedatives resolved in 1 49 1 1 hours and 922 patients who did not receive sedatives resolved in 1 38 0 9 hours FDA label",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}